Naomi Miyake

Diagnostic and prognostic impact of serum‐soluble UL16‐binding protein 2 in lung cancer patients

M. Nakamoto, E. Shimizu, S. Matsumoto, 2012, Cancer science.

Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness.

M. Nakamoto, A. Yamasaki, Miyako Takata, 2019, Yonago acta medica.

Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells.

M. Nakamoto, E. Shimizu, T. Igishi, 2012, Oncology reports.

Rapamycin induces p 53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells

M. Nakamoto, E. Shimizu, T. Igishi, 2012 .

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity

E. Shimizu, Y. Kanamori, T. Igishi, 2012, Cancer biology & therapy.

Evaluation of antigen-positive toxin-negative enzyme immunoassay results for the diagnosis of toxigenic Clostridium difficile infection.

M. Nakamoto, E. Shimizu, A. Yamasaki, 2018, The journal of medical investigation : JMI.